These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17603540)

  • 1. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.
    Rodina A; Vilenchik M; Moulick K; Aguirre J; Kim J; Chiang A; Litz J; Clement CC; Kang Y; She Y; Wu N; Felts S; Wipf P; Massague J; Jiang X; Brodsky JL; Krystal GW; Chiosis G
    Nat Chem Biol; 2007 Aug; 3(8):498-507. PubMed ID: 17603540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer.
    Workman P; Powers MV
    Nat Chem Biol; 2007 Aug; 3(8):455-7. PubMed ID: 17637775
    [No Abstract]   [Full Text] [Related]  

  • 3. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
    Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
    Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
    Zhang Q; Zhai S; Li L; Li X; Zhou H; Liu A; Su G; Mu Q; Du Y; Yan B
    Biochem Pharmacol; 2013 Aug; 86(3):351-60. PubMed ID: 23743233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
    Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
    Seo YH
    Arch Pharm Res; 2015 Oct; 38(10):1783-8. PubMed ID: 25855012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
    Lee KH; Jang AH; Yoo CG
    Am J Respir Cell Mol Biol; 2015 Sep; 53(3):412-21. PubMed ID: 25633180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.
    Bartling B; Lewensohn R; Zhivotovsky B
    Exp Cell Res; 2004 Aug; 298(1):83-95. PubMed ID: 15242764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.
    Ko JC; Chiu HC; Syu JJ; Chen CY; Jian YT; Huang YJ; Wo TY; Jian YJ; Chang PY; Wang TJ; Lin YW
    Biochem Biophys Res Commun; 2015 Jan; 456(1):506-12. PubMed ID: 25490383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
    Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.